Search

ObjectivesThis systematic review aimed to assess the effectiveness of submucosal tramadol injections in post-operative pain management following third molar surgical extraction.Materials and methodsDatabases, such as PubMed, Scopus, ScienceDirect, and Cochrane Library, were systematically searched using relevant keywords. Randomized clinical trials that met the inclusion criteria were assessed to determine the effectiveness of tramadol in managing acute post-operative pain following third molar surgery.ResultsIn total, seven studies with participants of 18 and over following randomized placebo-controlled trials were considered for the analysis. A submucosal injection of 2 ml (50–100 mg) of tramadol adjacent to the impacted mandibular third molar effectively controlled pain for up to 6–24 h following surgery. Non-serious adverse events, such as nausea, vomiting, and headache, were reported in two studies. Meta-analysis (subgroup analysis) revealed heterogeneity among the studies, demonstrating variability in the results across the included studies. In addition, tramadol demonstrated a significant decrease in post-operative pain.ConclusionSubmucosal tramadol is an efficient, safe, and dependable method for reducing post-operative acute pain, particularly in the first 6 h following impacted third molar surgery. However, due to the observed heterogeneity in the research, there is need for cautious interpretation of the findings and potential limitations in the evidence base. To enhance the quality of evidence on this topic, we strongly recommend conducting new RCTs using established methodologies.Clinical relevancePost operative pain following third molar surgeries is one of the common complications. Submucosal tramadol injections were found to be successful in reducing post extraction pain as well as other morbidities.

Objectives: It is commonly accepted that immediate implantation is the best option for patients since it shortens the time patients must wait for ultimate restoration and provides a predictable functional and aesthetic result. However, this approach is still controversial in patients with apical pathosis. The goal of this systematic review and meta-analysis was to determine the efficacy of immediate implant insertion in patients with apical pathosis. Material and methods: Between 2000 and 2023, PRISMA-compliant keywords were used to search PubMed, MEDLINE, CENTRAL, and the Cochrane Library. All English-language clinical studies that met PICOS criteria were included in a manual search. The included studies' demographic profile and event data for immediate dental implantation success in patients with or without apical pathosis were meta-analyzed using RevMan. The implant survival rate was assessed using risk ratio of plaque index and bleeding index. Begg's test using MedCalc and RevMan risk of bias assessment assessed publication bias. Results: A meta-analysis of 10 trials with 849 dental implantation patients found a substantial difference in initial implant placement success rates in infected sites. The pooled risk ratio for plaque index is 0.59 (95% CI: 0.36–0.96) with heterogeneity of Tau2 = 0.62, chi2 = 109.69, df = 11, I2 = 90%, z = 2.12, and p